Praxis Precision Medicines Wins FDA Breakthrough Status for Elsunersen in Rare Epilepsy
Phase 2 data showed 77% seizure reduction and sustained benefits up to 1 year.
NOTRELOAD AI
EB613 Set to Become First Once-Daily Oral Tablet for Osteoporosis as Entera Bio Advances to Phase 3
Entera Bio receives positive FDA feedback on its pivotal Phase 3 trial design for EB613, the potential first once-daily oral tablet to stimulate bone formation in postmenopausal women with osteoporosis.
DeepMind Talent Exodus Hits Alphabet: Nobel Winner John Jumper Joins Anthropic
Another major exit follows Noam Shazeer’s move to OpenAI.
No Efficacy or Safety Issues: Achieve Life Sciences Gets FDA CRL for Cytisinicline
Achieve Life Sciences received an FDA Complete Response Letter for its cytisinicline NDA due to manufacturing issues at a former facility. No efficacy or safety deficiencies were identified.
Dell and Super Micro Launch Nvidia Vera Rubin AI Servers, Sparking Fresh Market Buzz
Early shipments and bullish analyst targets signal strong 2026 growth.
Micron Partners with Anthropic on Memory, Supply, and AI Infrastructure Push
Micron Technology and Anthropic announce a major strategic partnership covering AI memory optimization, long-term supply, enterprise adoption, and Micron’s investment in Anthropic’s Series H round.